Investing.com - Humanigen reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Humanigen announced earnings per share of $-0.2300 on revenue of $221.0K. Analysts polled by Investing.com anticipated EPS of $-0.1805 on revenue of $260K.
Humanigen shares are down 95% from the beginning of the year, still down 97.59% from its 52 week high of $6.95 set on November 17, 2021.
Humanigen follows other major Healthcare sector earnings this month
Humanigen's report follows an earnings beat by Eli Lilly on November 1, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
Pfizer had beat expectations on November 1 with third quarter EPS of $1.78 on revenue of $22.6B, compared to forecast for EPS of $1.44 on revenue of $21.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar